|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
10/19/2005 5:13:16 PM
CAMARILLO, Calif.--(BUSINESS WIRE)--April 11, 2005--BioSource International, Inc. (Nasdaq:BIOI) today announced that its Board of Directors, in a special meeting held earlier today, voted unanimously to reject an unsolicited proposal from Bio-Rad Laboratories, Inc. (Amex:BIO) (Amex:BIOB), dated April 6, 2005, to acquire all of BioSource's outstanding shares at $8.50 per share in cash. The Board of Directors, after consultation with its legal and financial advisors, concluded that the proposed price is significantly below BioSource's inherent value. A copy of BioSource's letter to Bio-Rad regarding the Board of Directors' determination is attached to this press release.
The BioSource Board of Directors also announced that BioSource has retained UBS Investment Bank to act as financial advisor and Weil, Gotshal & Manges to act as legal advisor, to assist the Company in evaluating strategic alternatives, including a possible sale of the Company. In addition, the Company said that its 2005 annual meeting, presently scheduled for May 24, 2005, will be rescheduled to a future date.
|
|
|
|
|
|
|
|
|
|
|